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Therapy with lamivudine and
steroids in a patient with acute
hepatitis B and rapidly
progressive glomerulonephritis
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To the Editor: Tang et al.1 recently reported that lamivudine
(LAM) improves renal outcome in patients with chronic
hepatitis B virus (HBV) infection and membranous nephro-
pathy. We would like to add our experience on acute hepatitis
B and rapidly progressive glomerulonephritis.
A 36-year-old woman, previously healthy and hepatitis B
surface antigen (HBsAg) negative, presented in March 2005
with generalised oedema and macroscopic haematuria. Blood
pressure was 160/90 mm Hg. Laboratory data (Table 1)
showed high serum creatinine, massive proteinuria, and
alanine aminotransferase higher than 30 u.n.l., with evidence
of HBsAg, HBeAg, and HBV-DNA positive. Renal biopsy
showed mesangioproliferative glomerulonephritis with cres-
cents. HBsAg and HBcAg deposition in glomeruli was shown
by immunofluorescence by monoclonal F(ab) antibodies
(Figure 1a and b). LAM (100 mg/day) was started and alanine
aminotransferase rapidly decreased, but renal function worsen-
ed. Ten days later steroid (methylprednisolone 500 mg/day
intravenously for 3 days, then prednisone 1 mg/kg/day)
was added. After 1 week, alanine aminotransferase fell at
137 IU/l, serum HBV-DNA dropped to 3.3 103 UI/ml,
and renal function improved. The hypertension was treated
with angiotensin-converting enzyme inhibitors, diuretics,
and calcium antagonists. Four months later she underwent
HBeAg seroconversion, HBV-DNA became undetectable by
polymerase chain reaction and HBsAg was negative. Seven
months after alanine aminotransferase normalised, protei-
nuria cleared, creatinine clearance rose to 82 ml/min and
serum creatinine was normal (Table 1). Steroids were
stopped, while LAM was continued for 3 months after
HBsAg seroconversion.
Our report confirms the direct association between HBV
infection and development of nephropathy2 and supports the
efficacy and safety of LAM in patients with HBV-related
nephropathy.1,3 LAM, through its rapid and potent antiviral
action, allows immunosuppression to be performed effec-
tively without any undue effect on HBV replication or risk of
chronicity of infection.
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Table 1 | Laboratory data
23 March 2005 2 April 2005 9 April 2005 20 June 2005 25 July 2005 16 October 2005
Therapy LAM LAM+steroids LAM+steroids LAM+steroids LAM+steroids LAM
BUN (mg/dl) 128 182 192 82 42 43
Creatinine (mg/dl) 3.8 7.1 3.3 1.5 1.2 1.1
Creatinine clearance (ml/min) 14 6 18 61 60 82
Albumin (g/dl) 2 3.8 4 4.4 4 4.7
Proteinuria (g/24 h) 12 8.5 8 0.08
ALT (u.n.l. 31 IU/l) 900 331 137 259 40 23
Bilirubin (g/dl) 0.5 0.7 0.5 0.3 0.3 0.2
HBsAg/anti-HBs +/ +/ +/ / / /+
HBeAg/anti-HBe +/ +/ +/ / /+ /+
Anti-HBc IgM (Imx units) 2.48 1.47 0.4 0.2
HBV-DNA (UI/ml) 2.8 106 1.2 104 3.3 103 o2 102 o2 102 o2 102
ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; LAM, lamivudine.
a
b
Figure 1 | (a) HBcAg expressed as coarse granules in the nuclei
of most cells of the proximal renal tubules. One cell displays
cytoplasmic clumps of HBcAg. (b) HBsAg deposited in crescents in
a glomerulus and on the luminal border of some tubules.
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Is i.v. iron really superior in CKD
patients not on dialysis?
Kidney International (2006) 70, 1188. doi:10.1038/sj.ki.5000425
To the Editor: Van Wyck et al.1 administered 1 g intravenous
(i.v.) iron over the first 2 weeks, whereas oral iron was given
over 8 weeks. As the rates of administration of iron were
different, the appropriate comparison should be the propor-
tion of patients achieving the primary end point at the end of
10–12 weeks and make the results more clinically relevant. In
the analysis presented, it is assumed that patients who
achieved 1 g/dl increase in hemoglobin at 2 weeks would also
have the same response at 56 days. In the interest of
intention-to-treat, the authors should also present the data
for all patients randomized even when erythropoietin dose
was not stable at baseline. The authors should be cautious in
concluding that i.v. iron is safe in the long term. Progression
of chronic kidney disease takes years and it would appear
naive to declare safety of i.v. iron by reporting two estimated
glomerular filtration rates over a course of 56 days! Notably,
the improvement in hemoglobin with i.v. iron was only 0.3 g/
dl more in the i.v. iron group, and 2/30 patients who received
the high dose of 500 mg iron sucrose experienced severe
hypotension sufficient to visit the emergency room. Thus,
caution is warranted, when using high-dose i.v. iron. The
authors measured C-reactive protein, yet do not report the
data. Change in proteinuria was not reported and the
multivariate logistic model for odds of hemoglobin response
was also not presented as stated in the methods. These
additional data would help interpret the results of this trial
better.
1. Van Wyck DB, Roppolo M, Martinez CO et al. A randomized, controlled
trial comparing IV iron sucrose to oral iron in anemic patients with
nondialysis-dependent CKD. Kidney Int 2005; 68: 2846–2856.
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Response to Is i.v. iron really
superior in CKD patients not on
dialysis?
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Dr Agarwal1 raises a number of important questions. The
answer to the title question would seem to be yes, i.v. iron
is superior to oral iron. Moreover, the degree of difference
is clinically significant: in chronic kidney disease patients
with anemia (hemoglobin (Hb) o11 g/dl) without ery-
thropoiesis-stimulating agents (ESA) or without an in-
crease in ESA dose, i.v. iron administration will raise the
Hb higher, stimulate a Hb increase 41.0 g/dl more often,
achieve or exceed the target Hb threshold of X11.0 g/dl
more consistently, and replete iron stores more reliably
than oral iron therapy. The answer to whether we should
have included patients with ESA dose increases in the
analysis of efficacy is no. Increasing ESA doses, like
starting ESA anew, administering additional i.v. iron off
protocol, or transfusing the patient, introduces a co-
intervention. The penalty for including co-interventions is
the inability to isolate iron treatment effects. As we
discussed, previous randomized controlled trials that failed
to preclude co-interventions failed to show between-group
differences in patients assigned to i.v. iron or oral iron
treatment.2,3
Was the duration of the trial sufficient to show efficacy?
We demonstrated that the peak Hb response in both
treatment groups occurred before 42 days, well before
completion of the 56-day observation period. Among
patients assigned to oral iron, peak increase in Hb was
lower than in i.v.-treated patients, as we showed, but time
to peak increase did not differ between groups (Cox
proportional hazards model: 36.1 vs 39.9 days, oral vs i.v.;
P¼ 0.3481). Logistic regression analysis yielded only
baseline ferritin o100 ng/ml as a significant covariate in
increasing the odds of a positive Hb response, a result we
explored in more detail in the analyses we presented in
Table 2.
Was the duration of the trial sufficient to conclude that
i.v. iron, compared to oral iron, is safe in patients with
chronic kidney disease? Three randomized controlled
trials, including ours, have examined the effect of i.v. iron
administration compared to oral iron therapy on renal
function in chronic kidney disease patients. In the first,
patients given i.v. iron sucrose 300 mg monthly up to 6
months showed a rate of decline of renal function no
different from that seen in patients given oral iron.2 In the
second, patients assigned to oral iron therapy showed a
significant decline in ClCr, whereas their counterparts
given i.v. iron dextran 100 mg twice monthly up to 3
months showed no decline.4 Our results in patients who
received five 200 mg doses or two 500 mg doses of iron
sucrose showed a slower rate of decline of glomerular
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